Memantine is a dissociative substance of the adamantane class that produces long-lived dissociative effects when administered. It is a derivative of amantadine and is pharmacologically related to compounds like PCP, ketamine, and DXM, although its recreational use is comparatively rare. Memantine was first synthesized by Eli Lilly and Company in 1968 as a potential agent to treat diabetes.
Perspectives
“This drug is certainly fascinating. Not entirely enjoyable or fun, rather it just felt fundamentally and deeply neutral. Its essence was elusive and mysterious, it felt as though it was a drug that existed at the fringes of consciousness that simply was not meant to be understood.”
Build-updevelops with repeated use over days to weeks
Reset2–4 weeks for noticeable reduction
Tolerance Decay
Full tolerance
14dHalf tolerance
7dBaseline
~28d
Anecdotal reports suggest tolerance builds with frequent or daily use and decays over weeks of abstinence; cross-tolerance among NMDA antagonists is commonly reported by users but lacks controlled human data. Given memantine’s long half-life, apparent tolerance may reflect persistent baseline plasma levels rather than receptor-level adaptations. Data quality: anecdotal.